Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;128(1):42-47.
doi: 10.1038/s41416-022-02037-5. Epub 2022 Nov 8.

Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry

Michael E Kelly  1 , Niall J O'Sullivan  2 , Jarlath C Bolger  2 , Francesco Polignano  3 , Haney Youssef  4 , Andrew Renehan  5 , Lee Malcomson  5 , Sue Alves  6 , Tom Cecil  6 , Jürgen Mulsow  2 , Brendan Moran  6 , Faheez Mohamed  6 ; UK & Ireland Colorectal Peritoneal Metastases Registry
Collaborators, Affiliations
Review

Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry

Michael E Kelly et al. Br J Cancer. 2023 Jan.

Abstract

Background: The management of colorectal peritoneal metastases continues to be a challenge but recent evidence suggests cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can improve survival. Uncertainty about the relationship between age and tumour biology makes patient selection challenging particularly when reported procedure related morbidity is high and impact on survival outcomes unknown. The UK and Ireland Colorectal Peritoneal Metastases Registry was reviewed to assess the influence of age on efficacy of CRS and HIPEC.

Methods: A review of outcomes from the UK and Ireland Colorectal Peritoneal Metastases Registry was performed. Data from 2000 to 2021 were included from five centres in the UK and Ireland, and the cohort were sub-divided into three age groups; <45 years, 45-65 years and >65 years old. Primarily, we examined post-operative morbidity and survival outcomes across the three age groups. In addition, we examined the impact that the completeness of cytoreduction, nodal status, or adverse pathological features had on long-term survival.

Results: During the study period, 1138 CPM patients underwent CRS HIPEC. 202 patients(17.8%) were <45 years, 549 patients(48.2%) aged 45-65 years and 387 patients(34%) >65 years. Overall, median length of surgery (CRS and HIPEC), median PCI score and rate of HIPEC administration was similar in all three groups, as was overall rates of major morbidity and/or mortality. Complete cytoreduction rates (CC0) were similar across the three cohorts; 77%, 80.6% and 81%, respectively. Median overall survival for all patients was 38 months following complete cytoreduction.

Conclusion: Age did not appear to influence morbidity or long-term survival following CRS and HIPEC. When complete cytoreduction is achieved survival outcomes are good. The addition of HIPEC can be performed safely and may reduce local recurrence within the peritoneum.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
CC0 vs. CC1 + for the entire cohort.
Fig. 2
Fig. 2. Kaplan-Meier curve showing the three age cohorts, comparing CC0 vs. CC1+
CC0 vs. CC1+ across the three age cohorts.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Dietz MV, van Kooten JP, Said I, Brandt-Kerkhof ARM, Verhoef C, Bremers AJA, et al. Survival outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with synchronous versus metachronous onset of peritoneal metastases of colorectal carcinoma. Ann Surg Oncol. 2022; 29:6566–76. - PMC - PubMed
    1. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709–19. doi: 10.1016/S1470-2045(16)30500-9. - DOI - PubMed
    1. Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS Open. 2019;3:585–94. doi: 10.1002/bjs5.50179. - DOI - PMC - PubMed
    1. Lundy ME, Moaven O, Perry KC, Mangieri CW, Valenzuela CD, Russell GB, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of colorectal cancer with peritoneal dissemination: 30 years of experience at a single institution. J Am Coll Surg. 2022;234:546–56. doi: 10.1097/XCS.0000000000000091. - DOI - PMC - PubMed
    1. Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110:779–85. doi: 10.1002/jso.23728. - DOI - PubMed

Publication types